Affordable Access

Publisher Website

Effect of endothelin-1 in man—impact on basal and stimulated concentrations of luteinizing hormone, follicle-stimulating hormone, thyrotropin, growth hormone, corticotropin, and prolactin with and without pretreatment with nifedipine

Authors
Journal
Metabolism
0026-0495
Publisher
Elsevier
Publication Date
Volume
45
Issue
5
Identifiers
DOI: 10.1016/s0026-0495(96)90039-6

Abstract

Abstract In healthy men, intravenous (IV) endothelin-1 suppresses the growth hormone (GH)-releasing hormone (GHRH)-stimulated increase in GH and prolactin (PRL) and augments corticotropin (ACTH)-releasing factor (CRF)-stimulated secretion of ACTH. Since some actions of endothelin-1 on pituitary function in vitro are antagonized by calcium channel antagonists, we have studied the effect of pretreatment with oral nifedipine (10 mg, given before infusion of endothelin-1 or vehicle) on basal and stimulated concentrations of pituitary hormones in a group of healthy men (N = 6). The augmentative effect of endothelin-1 on CRF-induced ACTH secretion ( P < .05) was counteracted by pretreatment with nidefipine. Pretreatment with nifedipine further inhibited ( P < .01) the GHRH-induced increase in plasma concentrations of GH ( P < .05), which, in keeping with previous data, had already been reduced by IV endothelin-1 alone ( P < .05). Thus, both endothelin-1 and nifedipine influence pituitary hormone secretion in healthy man. However, nifedipine does not ubiquitously counteract the effects of endothelin-1 since it enhances some of its actions on the pituitary and diminishes others. Endothelin-1 may therefore influence pituitary function by mechanisms other than activation of calcium channels alone.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments